ARCHIVES

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

This article is from The Cancer Letter archive.

Vol. 17 No. 31 | August 2, 1991

Download PDF Visit The Full Archive

Related Articles

HHS To Award “Micro-Grants” For Public Health Programs.

July 20, 2001

DCT Board Approves Concepts Of Eight New Biological Response Modifiers Program

July 3, 1981

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

In Brief: FDA Opens Advisory Committee Consideration Of NDAs, Finds Discussion Is Not Inhibited

September 10, 1976

Banned Investigator Plans To Resume Clinical Trials Role

August 10, 1990

RTOG Finds Twice A Day Radiation For Advanced Head And Neck Cancer Improved Local Tumor Control Rate

August 25, 2000